Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer by Guldvik, IJ, Braadland, PR, Sivanesan, S, Ramberg, H, Kristensen, G, Tennstedt, P, Røder, A, Schlomm, T, Berge, V, Eri, LM, Lilleby, W, Mills, IG, Taskén, KA

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. by Jain, S, Lyons, C, Walker, S, McQuaid, S, Hynes, S, Mitchell, D, Pang, B, Logan, G, McCavigan, A, O'Rourke, D, McArt, D, McDade, S, Mills, I, Prise, K, Knight, L, Steele, C, Medlow, P, Berge, V, Katz, B, Loblaw, D, Harkin, D, James, J, O'Sullivan, J, Kennedy, R, Waugh, D

Molecular subgroup of primary prostate cancer presenting with metastatic biology. by Walker, SM, Knight, LA, McCavigan, AM, Logan, GE, Berge, V, Sherif, A, Pandha, H, Warren, AY, Davidson, C, Uprichard, A, Blayney, JK, Price, B, Jellema, GL, Steele, CJ, Svindland, A, McDade, SS, Eden, CG, Foster, C, Mills, IG, Neal, DE, Mason, MD, Kay, EW, Waugh, DJ, Harkin, DP, Watson, RW, Clarke, NW, Kennedy, RD